These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29633012)

  • 1. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA).
    Garcia-Santibanez R; Zaidman CM; Sommerville RB; Lopate G; Weihl CC; Pestronk A; Bucelli RC
    J Neurol; 2018 Jun; 265(6):1402-1409. PubMed ID: 29633012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD.
    Pascual-Goñi E; Collet R; Tejada-Illa C; Martín-Aguilar L; Caballero-Ávila M; Lleixà C; Novelli S; López-Pardo J; Sanfeliu AE; Mariscal A; Álvaro Gargallo Y; Martínez-Hernández E; Cocho D; Querol L
    J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):609-611. PubMed ID: 38341197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effect of medical therapy and rehabilitation in Chronic Ataxic Neuropathy with anti-Disialosyl IgM Antibodies (CANDA): a case report.
    Balestro G; Picelli A; Ortolani L; Marcante A
    Eur J Transl Myol; 2023 Jul; 33(3):. PubMed ID: 37522810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term efficacy of rituximab in chronic ataxic neuropathy associated with antiganglioside antibodies.
    Bertran Recasens B; Figueras-Aguirre G; Royo de Mingo I; Rubio MÁ
    Neurologia (Engl Ed); 2021 Mar; ():. PubMed ID: 33810892
    [No Abstract]   [Full Text] [Related]  

  • 5. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
    Le Cann M; Bouhour F; Viala K; Simon L; Tard C; Rossi C; Morel G; Lagrange E; Magy L; Créange A; Michaud M; Franques J; Echaniz-Laguna A; Antoine JC; Baron M; Arnulf B; Puma A; Delmont E; Maisonobe T; Leblond V; Roos-Weil D
    Blood; 2020 Nov; 136(21):2428-2436. PubMed ID: 32959046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CANOMAD syndrome with respiratory failure.
    Salamon A; Dézsi L; Radics B; Varga ET; Hortobágyi T; Tömösvári A; Vécsei L; Klivényi P; Rajda C
    Ideggyogy Sz; 2020 Mar; 73(3-4):141-144. PubMed ID: 32364342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies.
    Carreau C; Benoit C; Ahle G; Cauquil C; Roubertie A; Lenglet T; Cosgrove J; Meunier I; Veauville-Merllié A; Acquaviva-Bourdain C; Nadjar Y
    J Neurol Neurosurg Psychiatry; 2020 Oct; ():. PubMed ID: 33087424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy.
    Vallat JM; Duchesne M; Corcia P; Richard L; Ghorab K; Magy L; Mathis S
    Neurology; 2021 Feb; 96(5):214-225. PubMed ID: 33277411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature.
    Marastoni D; Africa L; Peretti A; Bocci S; Insana L; Ferrari S; Ginanneschi F; Zanette G; Fabrizi GM; Giannini F
    J Neurol; 2020 Aug; 267(8):2353-2361. PubMed ID: 32347337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment.
    Lehmann HC; Burke D; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):981-987. PubMed ID: 30992333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective.
    Kusunoki S; Willison HJ; Jacobs BC
    J Neurol Neurosurg Psychiatry; 2021 Mar; 92(3):311-318. PubMed ID: 33376111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy.
    Rajabally YA; Attarian S; Delmont E
    J Inflamm Res; 2020; 13():543-549. PubMed ID: 32982369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing.
    Roggenbuck D; Delmont E; Reinhold D; Schierack P; Conrad K; Boucraut J
    Mediterr J Rheumatol; 2020 Mar; 31(1):10-18. PubMed ID: 32411930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axonal variants of Guillain-Barré syndrome: an update.
    Shang P; Zhu M; Wang Y; Zheng X; Wu X; Zhu J; Feng J; Zhang HL
    J Neurol; 2021 Jul; 268(7):2402-2419. PubMed ID: 32140865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guillain-Barré Syndrome.
    Kaida K
    Adv Exp Med Biol; 2019; 1190():323-331. PubMed ID: 31760653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
    Bunschoten C; Jacobs BC; Van den Bergh PYK; Cornblath DR; van Doorn PA
    Lancet Neurol; 2019 Aug; 18(8):784-794. PubMed ID: 31076244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neurofascin autoantibody and demyelination.
    Kira JI; Yamasaki R; Ogata H
    Neurochem Int; 2019 Nov; 130():104360. PubMed ID: 30582947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-ganglioside Antibodies in Peripheral Nerve Pathology.
    Willison HJ
    Methods Mol Biol; 2018; 1804():173-188. PubMed ID: 29926408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gangliosides and Autoimmune Peripheral Nerve Diseases.
    Goodfellow JA; Willison HJ
    Prog Mol Biol Transl Sci; 2018; 156():355-382. PubMed ID: 29747820
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.